Open access peer-reviewed Edited Volume

COVID-19 Drug Development - Recent Advances, New Perspectives, and Applications

Arli Aditya Parikesit

Indonesia International Institute for Life Sciences, Indonesia

A researcher in transcriptomics, immunoinformatics, and structural bioinformatics, ISBB and APBIONET member, currently involved in COVID-19 Drug and Vaccine design. Dr. Parikesit was awarded his Ph.D. from the University of Leipzig, was previously affiliated with the University of Indonesia, and acted as a reviewer for the American Journal of applied sciences, American Journal of molecular biology, and Indonesian Journal of Biotechnology.


Molecular Docking Molecular Dynamics Biomolecular Modeling Homology Modeling In Vitro Drug Testing In Vivo Drug Testing Structural Biology Nano Delivery Prodrug Smart Drug Liposome Wet Lab

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and has manifested into different variants. Previously, the delta variant has compromised existing therapeutic and preventive options for this disease. Now, the omicron variant is beginning to replace the others. In this respect, strategies to treat and cure COVID-19 should be devised. In the light of pharmaceutical biotechnology, three different approaches could be catered to resolve this issue. First, Computer-Aided Drug Design (CADD) approach. Second, rational drug design in the wet lab approach. Third, is the advanced drug delivery system. These approaches are influenced heavily by advances in life sciences such as the inception of structural bioinformatics as an independent study, the establishment of nanobiotechnology as a standard approach in drug design, and high advancement in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions toward this ongoing COVID-19 pandemic, in the light of those advancements in life sciences.

Publishing process

Book initiated and editor appointed

Date completed: April 12th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: July 9th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: September 27th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: November 26th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Arli Aditya Parikesit

Dr. rer. nat. Arli Aditya Parikesit is the Vice Rector of Research and Innovation at Indonesia International Institute for Life Sciences (I3L). He finished both his bachelor’s and master’s degrees in chemistry at the Faculty of Mathematics and Natural Sciences, University of Indonesia. In order to pursue a degree in Bioinformatics, he accepted an offer from DAAD (German Academic Exchange Service) to conduct doctorate research at the Bioinformatics Group, Faculty of Informatics and Mathematics, University of Leipzig, Germany. His doctoral research is focused on the utilization of modern protein domain annotation techniques to the three domains of life. In addition, Dr. Arli is also an expert on immunoinformatics, bioinformatics algorithm, structural bioinformatics, in silico drug design, and in silico transcriptomics. Currently, Dr. Arli is devising a pipeline to apply his expertise to COVID-19 drug and vaccine designs.

View profile

Book chapters authored 3

Books edited 2

Introducing your Author Service Manager

Ms. Marica Novakovic

Ask a question

Book will be abstracted and indexed in